Department of Psychiatry, School of Medicine, James Cook University, Queensland 4811, Australia.
Neuropsychiatr Dis Treat. 2008 Dec;4(6):1181-91. doi: 10.2147/ndt.s3238.
Quetiapine has demonstrated efficacy in schizophrenia, bipolar disorder and in the treatment of specific symptom clusters such as agitation and sleep problems in mood disorders. In this review, randomized controlled studies demonstrating efficacy, safety and tolerability of quetiapine in major depressive disorder (MDD) and general anxiety disorder (GAD) are evaluated. The results show that quetiapine monotherapy and quetiapine augmentation of antidepressant treatment in MDD and GAD are efficacious for short-term and maintenance treatment at a dose range between 50 and 300 mg/day. Quetiapine appears to have a specific but overall mild side-effect profile, though, some adverse effects such as sedation and somnolence may lead to withdrawal from treatment in some patients. Overall, the available evidence suggests that there is a significant role for quetiapine in the treatment of MDD and GAD.
喹硫平已被证明在精神分裂症、双相情感障碍以及治疗心境障碍中的特定症状群（如激越和睡眠问题）方面有效。在本次综述中，评估了显示喹硫平在重度抑郁症（MDD）和广泛性焦虑症（GAD）中的疗效、安全性和耐受性的随机对照研究。结果表明，喹硫平单药治疗以及作为抗抑郁治疗的增效治疗，在 MDD 和 GAD 中，在短期和维持治疗中均有效，剂量范围为 50 至 300mg/天。喹硫平似乎具有特定但总体上较轻的副作用特征，但一些不良反应，如镇静和嗜睡，可能导致一些患者停药。总体而言，现有证据表明，喹硫平在治疗 MDD 和 GAD 方面具有重要作用。
